Late-stage trials suggest Lilly’s tirzepatide, sold under Mounjaro, could be a more effective obesity drug that Ozempic or Wegovy, and the company expects a regulatory decision by the end of the year.
it is pushing for fast-track approval to greenlight diabetes drug tirzepatide, marketed as Mounjaro, for weight loss after promising clinical trial results, adding a potentially powerful tool to a growing arsenal of obesity drugs that are proving to be both hyped hits and essential medicines tackling a key public health problem.
The findings suggest tirzepatide, given by injection once a week, could be a more powerful weight loss aid than other obesity drugs on the market, notably Novo Nordisk’s Ozempic and Wegovy. The “degree” of weight loss in the trial is greater than that from other late-stage trials for overweight or obesity and type 2 diabetes, explained Jeff Emmick, senior vice president for product development at Lilly.
The findings, which have not been published in full or subjected to external peer review, add to previous research on overweight or obese people without diabetes, whichLilly said it plans to finalize its submission with the Food and Drug Administration for a fast-track approval to sell tirzepatide to help overweight or obese people without diabetes manage their weight.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Popular diabetes drug Mounjaro could be FDA-approved for weight loss this year, company saysA popular drug currently approved to treat Type 2 diabetes could soon also be approved for weight loss.
Consulte Mais informação »
Eli Lilly stock up premarket as company’s Q1 revenue beats and it raises guidanceEli Lilly & Co. shares rose 2% premarket Thursday, after the company posted first-quarter earnings showing a revenue beat and raised its full-year guidance....
Consulte Mais informação »
People with diabetes lost up to 34 pounds taking Eli Lilly drug, company saysAn Eli Lilly drug helped obese patients with Type 2 diabetes lose 15% of their body weight, or about 34 pounds, on average, in a late-stage clinical trial, the drugmaker says.
Consulte Mais informação »
Mounjaro Helps Diabetes Patients Lose ‘Meaningful’ Weight, Study ShowsMounjaro might be the next drug—after Ozempic—to upend the weight-loss market after a study showed it helped overweight and obese patients with Type 2 diabetes lose up to 15.7% of their body weight
Consulte Mais informação »
Powerful new obesity drug poised to upend weight loss careA diabetes drug being tested for weight loss is poised to further upend obesity care. Drugmaker Eli Lilly and Co. reported Thursday that its drug tirzepatide helped people with diabetes who were overweight or had obesity lose up to 16% of their body weight over 17 months in a late-stage trial. For those without the disease, the drug has prompted losses of more than 20% of body weight. Known as Mounjaro for diabetes use, the drug has been used “off label” for weight loss since last year. Lilly is applying for fast-track approval from U.S. regulators and expects a decision this year. Analysts have predicted tirzepatide could become one of the top-selling drugs ever, with annual sales of more than $50 billion.
Consulte Mais informação »
Eli Lilly’s tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in late-stage trialEli Lilly & Co. said Thursday its tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in a late-stage...
Consulte Mais informação »